Abstract
The establishment of a link between VEGF, hypoxia and ALS pathogenesis placed angiogenic factors and oxidative stress at the focal point for further studies. Recreation of a phenotype strikingly similar to that of mutant SOD1 mouse and human ALS, like muscle weakness and atrophy owing to lower motor neuron degeneration was observed following the targeted deletion of the hypoxia response element (HRE) from promoter of mouse vascular endothelial growth factor (VEGF). The crucial link between vasculature, angiogenic molecules and motor neuron degeneration has thus been constantly scrutinized. In this review, we have proposed to correlate human, in vitro and cadaveric studies so as to find out whether molecules like VEGF and various others, at the interface of neurovascular network and oxidative stress, have a prognostic, diagnostic and therapeutic potential for treatment of a fatal neurodegenerative disorder namely ALS.
Keywords: Amyotrophic Lateral Sclerosis (ALS), angiogenin, biomarkers, neurovascular, optineurin, oxidative stress, soluble VEGFR1 (sVEGFR1)/soluble fms-like tyrosine kinase-1 (sFLT-1), transactive response DNA-binding protein 43 (TDP-43), MND, (NCDs)
Current Neurovascular Research
Title:Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Volume: 9 Issue: 4
Author(s): Himshikha Bhutani and Akshay Anand
Affiliation:
Keywords: Amyotrophic Lateral Sclerosis (ALS), angiogenin, biomarkers, neurovascular, optineurin, oxidative stress, soluble VEGFR1 (sVEGFR1)/soluble fms-like tyrosine kinase-1 (sFLT-1), transactive response DNA-binding protein 43 (TDP-43), MND, (NCDs)
Abstract: The establishment of a link between VEGF, hypoxia and ALS pathogenesis placed angiogenic factors and oxidative stress at the focal point for further studies. Recreation of a phenotype strikingly similar to that of mutant SOD1 mouse and human ALS, like muscle weakness and atrophy owing to lower motor neuron degeneration was observed following the targeted deletion of the hypoxia response element (HRE) from promoter of mouse vascular endothelial growth factor (VEGF). The crucial link between vasculature, angiogenic molecules and motor neuron degeneration has thus been constantly scrutinized. In this review, we have proposed to correlate human, in vitro and cadaveric studies so as to find out whether molecules like VEGF and various others, at the interface of neurovascular network and oxidative stress, have a prognostic, diagnostic and therapeutic potential for treatment of a fatal neurodegenerative disorder namely ALS.
Export Options
About this article
Cite this article as:
Bhutani Himshikha and Anand Akshay, Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?, Current Neurovascular Research 2012; 9 (4) . https://dx.doi.org/10.2174/156720212803530654
DOI https://dx.doi.org/10.2174/156720212803530654 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine
Current Alzheimer Research Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Sirtuins as Possible Targets in Neurodegenerative Diseases
Current Drug Targets Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Histone Deacetylase Inhibitors: Therapeutic Agents and Research Tools for Deciphering Motor Neuron Diseases
Current Medicinal Chemistry Applications of Human Umbilical Cord Blood Cells in Central Nervous System Regeneration
Current Stem Cell Research & Therapy Gene Therapy Approaches to Ataxias
Current Gene Therapy Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?
Current Alzheimer Research Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science